CELG.RT
UBS Group’s Bristol-Myers Squibb Company Contingent Value Rights CELG.RT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $336 | Buy |
13,450
+290
| +2% | +$7 | ﹤0.01% | 8536 |
|
|
2025
Q1 | $659 | Buy |
13,160
+11,152
| +555% | +$558 | ﹤0.01% | 8380 |
|
|
2024
Q4 | $98 | Sell |
2,008
-1,659
| -45% | -$81 | ﹤0.01% | 8407 |
|
|
2024
Q3 | $176 | Buy |
3,667
+3,636
| +11,729% | +$175 | ﹤0.01% | 7873 |
|
|
2024
Q2 | $1 | Buy |
31
+1
| +3% | – | ﹤0.01% | 8266 |
|
|
2024
Q1 | $2 | Sell |
30
-1,996
| -99% | -$133 | ﹤0.01% | 8007 |
|
|
2023
Q4 | $182 | Buy |
2,026
+2,016
| +20,160% | +$181 | ﹤0.01% | 7621 |
|
|
2023
Q3 | $1 | Sell |
10
-398
| -98% | -$40 | ﹤0.01% | 8226 |
|
|
2023
Q2 | $45 | Sell |
408
-232
| -36% | -$26 | ﹤0.01% | 7527 |
|
|
2023
Q1 | $77 | Buy |
+640
| New | +$77 | ﹤0.01% | 8177 |
|
|
2022
Q4 | – | Sell |
-26,786
| Closed | -$4K | – | 9527 |
|
|
2022
Q3 | $4K | Buy |
26,786
+4,894
| +22% | +$731 | ﹤0.01% | 8234 |
|
|
2022
Q2 | $3K | Sell |
21,892
-209
| -0.9% | -$29 | ﹤0.01% | 8244 |
|
|
2022
Q1 | $3K | Buy |
22,101
+22,083
| +122,683% | +$3K | ﹤0.01% | 8370 |
|
|
2021
Q4 | $1K | Sell |
18
-1,451
| -99% | -$80.6K | ﹤0.01% | 8827 |
|
|
2021
Q3 | $0 | Buy |
1,469
+700
| +91% | – | ﹤0.01% | 8388 |
|
|
2021
Q2 | $0 | Buy |
769
+751
| +4,172% | – | ﹤0.01% | 8277 |
|
|
2021
Q1 | $0 | Hold |
18
| – | – | ﹤0.01% | 7931 |
|
|
2020
Q4 | $0 | Sell |
18
-25
| -58% | – | ﹤0.01% | 7364 |
|
|
2020
Q3 | $0 | Sell |
43
-4,761
| -99% | – | ﹤0.01% | 7102 |
|
|
2020
Q2 | $2K | Buy |
4,804
+3,425
| +248% | +$1.43K | ﹤0.01% | 6752 |
|
|
2020
Q1 | $1K | Sell |
1,379
-7,531
| -85% | -$5.46K | ﹤0.01% | 6814 |
|
|
2019
Q4 | $4K | Buy |
+8,910
| New | +$4K | ﹤0.01% | 6570 |
|